GlassScriptPhysician profile
Sarin Siriamonthep
NPI 1336694843
$1,571.85
in general payments reported to CMS, 2019-2025
17 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2021: $149 · 2022: $239 · 2023: $77.30 · 2024: $99.19 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $306.30 | 2019 | |
| Eyevance Pharmaceuticals LLC | $167.08 | 2021-2022 | |
| Alcon Vision LLC | $157.58 | 2022-2025 | Simbrinza, Eysuvis |
| Sun Pharmaceutical Industries INC. | $145.50 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $138.06 | 2019 | |
| Shire North American Group INC | $100.49 | 2019 | |
| Allergan, INC. | $99.82 | 2019 | |
| Harrow Eye, LLC | $99.19 | 2024 | Vevye |
| Coopervision INC. | $93.74 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $73.84 | 2025 | Xdemvy |
| Visioneering Technologies, INC. | $47.83 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.39 | 2019-2021 | |
| Rxsight INC | $27.54 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Oyster Point Pharma, INC. | $26.77 | 2025 | Tyrvaya |
| Abbvie INC. | $21.47 | 2023 | Lumigan, Vuity, Alphagan P |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $15.84 | 2022 | |
| Horizon Therapeutics Plc | $15.41 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarin Siriamonthep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.